ICD-10-CM 2027 diagnosis code
T50.0X5Adverse effect of mineralocorticoids and their antagonists
T50.0X5 is a header code, so it can't be reported by itself. Choose one of the 3 more specific codes beneath it and add the required 7th character.
Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS, effective October 1, 2026. Updated September 29, 2026. About our data
About T50.0X5
T50.0X5 is the ICD-10-CM diagnosis code for adverse effect of mineralocorticoids and their antagonists. It belongs to category T50 (poisoning by, adverse effect of and underdosing of diuretics and other and unspecified drugs, medicaments and biological substances), block T36-T50 (poisoning by, adverse effects of and underdosing of drugs, medicaments and biological substances) and chapter 19 (injury, poisoning and certain other consequences of external causes). It is a header code, so it can't be reported by itself; one of its 3 subcodes must be used instead.
Within T50.0X (poisoning by, adverse effect of and underdosing of mineralocorticoids and their antagonists), T50.0X5 is specifically for adverse effect of mineralocorticoids and their antagonists. Related codes cover poisoning by mineralocorticoids and their antagonists, accidental (unintentional) (T50.0X1), poisoning by mineralocorticoids and their antagonists, intentional self-harm (T50.0X2), poisoning by mineralocorticoids and their antagonists, assault (T50.0X3), poisoning by mineralocorticoids and their antagonists, undetermined (T50.0X4) and underdosing of mineralocorticoids and their antagonists (T50.0X6).
Codes in this range require a 7th character: A for initial encounter, D for subsequent encounter and S for sequela. Use placeholder "X" characters to fill any empty positions before the 7th character.
It has been part of ICD-10-CM since the code set took effect on October 1, 2015 and hasn't changed since.
7th character
The appropriate 7th character is to be added to each code from category T50
Notes that apply from higher levels
Instructions written at a parent level also apply to T50.0X5.
Table of Drugs & Neoplasms entries
- Aldactone — Adverse effect
- Aldosterone — Adverse effect
- Antagonist › Aldosterone — Adverse effect
- Canrenoic acid — Adverse effect
- Canrenone — Adverse effect
- Corticosteroid › mineral — Adverse effect
- Deoxycortone — Adverse effect
- Desoxycorticosteroid — Adverse effect
- Desoxycortone — Adverse effect
- Fludrocortisone — Adverse effect
- Fluorhydrocortisone — Adverse effect
- Mineralocorticosteroid — Adverse effect
- Potassium (salts) NEC › canrenoate — Adverse effect
- Salt-retaining mineralocorticoid — Adverse effect
- Spironolactone — Adverse effect
Code history
- 2016
- 2017
- 2018
- 2019
- 2020
- 2021
- 2022
- 2023
- 2024
- 2025
- 2026
- 2027
- FY2016 (effective 10/1/2015): Added (first year of ICD-10-CM)
- No changes since FY2016.
Common questions about T50.0X5
Is T50.0X5 billable?
- No. T50.0X5 is a header code. Report one of its more specific subcodes instead.